Evidence types
Basic science articles covering early-stage IBD research, disease mechanisms, lab findings, microbiome work, genetics, and experimental models.
Page 13 of 15 · 708 articles
The paper identifies microbiome-derived peptides that can directly block TLR4 signaling and reduce intestinal inflammation in mice; this reveals a new microbiome–immune mechanism that could inform future IBD treatments.
The study suggests a cellular redox pathway (selenium vs thiol axis) that is altered differently in Crohn's disease versus colorectal cancer, which could point to disease vulnerabilities and possible links to treatment...
The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.
The study links a traditional herbal formula to improved colitis in mice and to changes in bile-acid metabolism through the FXR–FGF15 pathway, suggesting a mechanistic route that could inform future preclinical or...
Researchers are investigating RBM47 because it influences RNA processing and immune pathways that could modify inflammation and disease processes relevant to IBD. If borne out, RBM47 could become a biomarker or...
Researchers identified a defined pectin from Sanguisorba officinalis that reduced inflammatory cytokine release in cells and improved outcomes in a mouse colitis model, suggesting a new lead for IBD drug discovery.
Cure8 found this source from Journal of physiological investigation, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. Open...
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Genetic...
If organoid transplantation can be translated to people, it could offer a new way to repair inflamed colonic lining and promote mucosal healing when current therapies are insufficient. The approach also highlights links...
The study suggests a multi-component herbal formula may affect inflammation, the intestinal barrier, epithelial repair, the gut microbiome, and fecal metabolites in a mouse colitis model—topics relevant to understanding...
This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.
This study describes a lab-stage engineered probiotic–silver nanoparticle therapy that reduced inflammation and promoted colon repair in an animal colitis model; it highlights new molecular targets (Wnt signaling and...
Identifies a redox-sensitive NOX1–ROS–IκBζ pathway that may sustain intestinal inflammation in IBD and points to a new molecular target for future therapies.
The study identifies a specific polysaccharide fraction (VPS-30) that reduced inflammation and improved gut barrier markers in cell and mouse models of colitis, suggesting a possible new functional-food lead for...
Researchers and clinicians are exploring cGAS/STING as a novel immune pathway linked to mucosal barrier function and inflammation in UC. Modulators of this pathway could become future targeted treatments, so patients and...
Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...
The systems view could explain limits of single-cytokine therapies and point toward multi-layer, precision approaches that better match a patient’s specific immune, genetic, and microbial context.
The study links ER stress and defective autophagy to increased claudin-2 and tight-junction dysfunction—mechanisms relevant to barrier loss in IBD. Targeting this pathway could eventually inform therapies to preserve...
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
AIEC is linked to IBD pathogenesis but is defined by lab assays rather than clear genetic markers. This paper presents a practical assay to detect cell invasion even when isolates are resistant to gentamicin, which could...
Targeting STING may reduce inflammatory signaling that contributes to ulcerative colitis; a safer, more potent STING inhibitor could become a new therapeutic approach if later-stage studies confirm benefit and safety.
This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...
This study identifies a specific probiotic–commensal interaction that improved colitis in mice and points to a metabolite (phosphatidylcholine) and metabolic pathway that might help repair the gut barrier — a pathway...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Chinese Journal of...
Patients and clinicians often ask whether herbal formulas or plant compounds can help IBD. This preclinical study identifies quercetin and the PI3K–Akt pathway as potential mechanisms, which may guide future research...
The study suggests JAK and TYK2 inhibitors can directly change epithelial inflammatory signaling and proliferation in UC, which may be relevant to healing of the gut lining and how different drugs work beyond immune...
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
The paper describes a potential new anti-inflammatory/hepatoprotective candidate (a cyanobacterium extract) tested in mouse models of liver injury and IBD — early-stage research that could guide future studies but is not...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
The study suggests nanoplastic particles can alter intestinal barrier function, goblet cells, mucin secretion, and inflammation-related gene expression in models with genetic susceptibility to Crohn’s disease.
Researchers are exploring targeted nanodelivery of miR-497 to reduce oxidative stress and shift immune cells toward tissue-repairing states — a novel preclinical strategy that could eventually lead to new treatments for...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
This study suggests a specific probiotic strain may help reduce colitis in mice by changing the gut microbiome and boosting host phosphatidylcholine production — a pathway that could be relevant to gut barrier repair in...
A new patient-derived “Colon Chip” reproduces key features of Crohn’s disease and ulcerative colitis in the lab and points to fibroblasts as active drivers of inflammation and early cancer-associated changes — insights...
Researchers exploring new anti-inflammatory or antioxidant compounds for ulcerative colitis may find sanggenol L’s effects on Nrf2/HO-1 and TLR4/p65 signalling of interest. Patients should note this is early-stage,...
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
The study identifies a food-derived compound that improved colitis in lab models and acted on JAK/STAT3 signaling and intestinal barrier proteins—pathways relevant to IBD inflammation and mucosal healing.
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
Identifies a microbiome-derived protein that inhibits a protease linked to epithelial damage in IBD and shows protective effects in lab and mouse models, pointing to a new therapeutic strategy focused on barrier...
The study tests a multi-targeted biohybrid that could—if translated—help address inflammation, oxidative stress, and dysbiosis together, a combination that current single-target IBD treatments often do not address.
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are...
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.
A traditional medicine formulation (Hudi capsules) relieved colitis signs in mice and appears to stimulate Wnt/β-catenin–dependent epithelial regeneration, which could point to new therapeutic directions for mucosal...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
Researchers tested manumycin A in a standard mouse colitis model and observed reduced inflammation and tissue injury, suggesting the compound might be a candidate for further IBD drug development.
